Considerations for Metabolite Pharmacokinetic Data in Bioavailability/Bioequivalence Assessments

Abstract

In recent years, the assessment of metabolite pharmacokinetic data has been increasingly on the rise in several types of clinical pharmacology studies including bioavailability/bioequivalence assessments of drug formulations. While the importance of pharmacokinetic data of metabolite(s) are well accepted, there appears to be reluctance on the part of scientific community to use such data in a prospective manner in the establishment of bioavailability/bioequivalence of marketed products and/or drugs in development. This review highlights the current trends that suggest that metabolite(s) data are being considered with or without the parent pharmacokinetic data in bioavailability/bioequivalence studies with numerous case studies. Also, some useful considerations from both bioanalytical and pharmacokinetic perspectives are proposed.

Key words

Bioavailability, assessments - Bioequivalence, assessments - Metabolites, pharmacokinetic data - Parent compounds, bioavailability, bioequivalence

• Literature

• 1 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry (Draft Guidance): In vivo bioequivalence studies based on population and individual bioequivalence approaches, October 1997
• 2 Colburn WA, Keefe DL. Bioavailability and bioequivalence: average, population and/or individual. J Clin Pharmacol. 2000; 40: 559-560
• 3 Yacobi A, Masson E, Moros D, Ganes D, Lapointe C, Abolfathi Z et al Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. J Clin Pharmacol. 2000; 40: 826-835
• 4 Schumaker RC, Metzler CM. The phenytoin trial is a case study of individual bioequivalence. Drug Inf J. 1998; 32: 1063-1072
• 5 Zariffa NM, Patterson SD. Population and individual bioequivalence: lessons from real data and simulation studies. J Clin Pharmacol. 2001; 41: 811-822
• 6 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Final guidance: BA and BE studies for orally administered drug products — general considerations 2000
• 7 Srinivas NR. Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus?. J Clin Pharmacol. 2004; 44: 115-119
• 8 Mehvar R, Jamali F. Bioequivalence of chiral drugs. Stereo-specific versus non-stereospecific methods. Clin Pharmacokin. 1997; 33: 122-141
• 9 Boni JR, Korth-Bradley JM, Richards LS, Chiang ST, Hicks DR, Benet LZ. Chiral bioequivalence: effect of absorption rate on racemic etodolac. Clin Pharmacokin. 2000; 39: 459-469
• 10 Garcia-Arieta A, Abad-Santos F, Rodriguez-Martinez MA, Varas-Polo Y, Novalbos J, Laparidis N et al An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies. Chirality. 2005; 17: 470-475
• 11 Jackson AJ, Robbie G, Marroum P. Metabolites and bioequivalence. Past and present. Clin Pharmacokin. 2004; 43: 655-672
• 12 Midha KK, Rawson MJ, Hubbard JW. The role of metabolites in bioequivalence. Pharm Res. 2004; 21: 1331-1344
• 13 The European Agency for the Evaluation of Medicinal Products, Committee for Products, Committee for proprietary medicinal products. Note for guidance on the investigation of bioavailability/bioequivalence. CPMP/EWP/QWP/1401/98, London, 26 July 2001
• 14 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioavailability and Bioequivalence studies for orally administered drug products-general considerations, July 2002
• 15 Quetglas EG, Campanero MA, Sadaba B, Escolar M, Azanza JR. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. Arzneimittelforschung. 2008; 58: 283-287
• 16 Zou JJ, Ji HJ, Wu DW, Yao J, Hu Q, Xiao DW et al Bioequivalence and pharmacokinetic comparison of a single 200 mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. Clin Ther. 2008; 30: 1651-1657
• 17 Xu FG, Zhang ZJ, Dong HJ, Tian Y, Liu Y, Chen Y. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. Arzneimittelforschung. 2008; 58: 117-121
• 18 Mignini F, Tomassoni D, Streccioni V, Traini E, Amenta F. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. Clin Exp Hypertens. 2008; 30: 95-108
• 19 Rojanasthien N, Nasangiam N, Kumsorn B, Roongapinun S, Jengjareon A. Pharmacokinetics and bioequivalence study of the two 20-mg quinapril hydrochloride tablet formulations in healthy Thai male volunteers. J Med Assoc Thai. 2008; 91: 739-46
• 20 Bahrami G, Mohammadi B, Sisakhtnezhad S. High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of Clopidogrel in human serum: Application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 864: 168-172
• 21 Lainesse A, Ozlap Y, Wong H, Alpan RS. Bioequivalence study of Clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004; 54: 600-604
• 22 Patel BN, Sharma N, Sanyal M, Shrivastav PS. Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylen-lafaxine in human plasma and its application to a bioequivalence study. J Pharm Biomed Anal. 2008; a 47: 603-11
• 23 Patel BN, Sharma N, Sanyal M, Prasad A, Shrivastav PS. High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. Biomed Chromatogr. 2008; 22: 1213-1224
• 24 Georgita C, Albu F, David V, Medvedovici A. Nonlinear calibrations on the assay of diltiazem and two of its metabolites from plasma samples by means of liquid chromatography and ESI/MS2 detection: Application to a bioequivalence study. Biomed Chromatogr. 2008; 22: 289-297
• 25 Di Girolamo G, Opezzo JA, Schere D, Gonzalez CD, Moncalvo JJ. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?. Expert Opin Pharmacother. 2007; 8: 1415-1423
• 26 Sora DL, Udrescu S, David V, Medvedovici A. Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. Biomed Chromatogr. 2007; 21: 1023-1029
• 27 Bienert A, Brzeziniski R, Szalek E, Dubai V, Grzeskowiak E, Dyderski S et al Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2006; 56: 723-728
• 28 Oliveria CH, Mederios Silva R, Santagada V, Caliendo G, Perissutti E, Prado Galuppo M et al Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration. Int J Clin Pharmacol Ther. 2006; 44: 142-148
• 29 Gatchev E, Brater M, de Mey C. Bioequivalence of a novel oral metronidazole formulation. Arzneimittelforschung. 2006; 56: 612-616
• 30 Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A et al Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006; 46: 282-290
• 31 Brewster M, Smith JR, Dutkowski R, Robson R. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: A cross-over, randomized, open-label study. Vaccine. 2006; 24: 44-46
• 32 Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R et al Simultaneous quantification of atorvasta-tin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomed Chromatogr. 2006; 20: 924-936
• 33 Mendoza L, Hajduch M, Plausinaitu R, Platilova V, Emritte N, Svoboda M. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers. Pharmazie. 2006; 61: 805-806
• 34 Vlase L, Bodiu B, Leucuta SE. Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. Arzneimittelforschung. 2005; 55: 664-668
• 35 Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS. Studies on the bioequivalence of different strengths of tablets containing clarithromycin. Arzneimit-telforschung. 2004; 54: 588-593
• 36 Srinivas NR. Changing need for bioanalysis during drug development. Biomed Chromatogr. 2008; 22: 235-243
• 37 Srinivas NR. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed Chromatogr. 2006; 20: 383-414
• 38 Srinivas NR. Dodging matrix effects in liquid chromatography tandem mass spectrometric assays – Compilation of key learnings and perspectives. Biomed Chromatogr. 2008; DOI:10.1002/bmc.1152.
• 39 Chambers E, Wagrowski-Diehl D, Lu Z, Mazzeo J. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B. 2007; 852: 22-34
• 40 Liang HR, Foltz RL Meng M, Bennett P. Ionization enhancement in atmospheric pressure chemical ionization and suppression in electrospray ionization between target drugs and stable-isotope-labeled internal standards in quantitative liquid chromatography/tandem mass spectrometry. Rapid Comm Mass Spectrom. 2003; 17: 2815-2821
• 41 Jemal M, Ouyang Z, Chen B, Teitz D. Quantiation of the acid and lactone forms of atorvastatin and its biotransformation products in humans serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Comm Mass Spectr. 1999; 13: 1003-1015
• 42 Srinivas NR. Applicability of nonlinear calibration regression for the determination of parent and metabolite(s) in bioequivalence assessments. Biomed Chromatogr. 2008; 22: 1315-1317
• 43 Medvedovici A, Sora DL, Ionesscu S, Hillberand M, David V. Characterization of a new norfloxacin metabolite monitored during a bioequivalence study by means of mass spectrometry and quantum computation. Biomed Chromatogr. 2008; 22: 1100-1107
• 44 Solans A, Izquierdo I, Donado E, Antonijoan R, Peña J, Nadal T et al Pharmacokinetic and safety profile of rupata-dine when coadministered with azithromycin at steady-state levels: A randomized, open-label, two-way, crossover, phase I study. Clin Ther. 2008; 30: 1639-1650
• 45 Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006; 46: S192-S201
• 46 Wang C, Quan LH, Guo Y, Liu CY, Liao YH. Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. Int J Pharm. 2007; 337: 155-160
• 47 Uemura N, Onishi T, Mitaniyama A, Kaneko T, Ninomiya K, Nakamura K et al Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 2005; 25: 199-208